PeptideDB

CFL-137 708-06-5

CFL-137 708-06-5

CAS No.: 708-06-5

CFL-137 is a selective KRasG12C inhibitor. CFL-137 exhibits antiproliferative properties. CFL-137 exhibits antitumor pro
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

CFL-137 is a selective KRasG12C inhibitor. CFL-137 exhibits antiproliferative properties. CFL-137 exhibits antitumor properties. CFL-137 has the potential to be used in lung cancer research.

Physicochemical Properties


Molecular Formula C11H8O2
Molecular Weight 172.18
Exact Mass 172.052
CAS # 708-06-5
Related CAS # 708-06-5
PubChem CID 12819
Appearance Light yellow to brown solid
Density 1.3±0.1 g/cm3
Boiling Point 305.8±0.0 °C at 760 mmHg
Melting Point 82-85ºC
Flash Point 134.3±13.0 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.719
LogP 2.84
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 2
Rotatable Bond Count 1
Heavy Atom Count 13
Complexity 191
Defined Atom Stereocenter Count 0
SMILES

O([H])C1C([H])=C([H])C2=C([H])C([H])=C([H])C([H])=C2C=1C([H])=O

InChi Key NTCCNERMXRIPTR-UHFFFAOYSA-N
InChi Code

InChI=1S/C11H8O2/c12-7-10-9-4-2-1-3-8(9)5-6-11(10)13/h1-7,13H
Chemical Name

2-hydroxynaphthalene-1-carbaldehyde
Synonyms

CFL-137
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets KRAS(G12C)
ln Vitro H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, and CCD-exhibited antiproliferative effects after 72 hours of exposure to CFL-137. The IC50 values of 986Sk cells are 11.4, 24.2, 24.5, 12.3, 43.3, 44.5, 27.63, 32.4, 46.9, 26.2, 25.0, 10.8, 66.2 µM [1].
ln Vivo CFL-137 (5 mg/kg for 5 treatments; 15 mg/kg for 5 treatments; 30 mg/kg for 3 treatments; ip) subcutaneous human lung carcinoma H1792 (KRasG12C mutant) and LCLC-103H (KRasWT)
Animal Protocol Animal/Disease Models: NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors) [1]
Doses: 5 mg/kg, 5 treatments; Growth of mouse tumor model [1]. 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments: intraperitoneal (ip) injection
Experimental Results: Tumor growth was diminished by 32.5% compared to controls in the KRasG12C mutation model.
References

[1]. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212.

Additional Infomation 2-hydroxy-1-naphthaldehyde is a member of the class of naphthaldehydes that is naphthalene-1-carbaldehyde substituted by a hydroxy group at position 2. Active core of sirtinol (CHEBI:73158). It is a member of naphthaldehydes and a member of naphthols.

Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 5.8079 mL 29.0394 mL 58.0788 mL
5 mM 1.1616 mL 5.8079 mL 11.6158 mL
10 mM 0.5808 mL 2.9039 mL 5.8079 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.